In addition, the DPP4 inhibitors vildagliptin [12] and sitagliptin [13] suppressed postprandial elevation of triglycerides and also ameliorated dyslipidemia in T2DM patients [14]. This evidence concerns the gene DPP4 and metabolic syndrome.